ArticleJournal of clinical medicine2025
How the Latest Guidelines Are Changing the Diagnostic and Therapeutic Landscape of Arterial Hypertension.
Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Age, Sex, and Waist-to-Height Ratio Approach the Discrimination of Fifty-Four Model Inputs for Prevalent Hypertension: An Explainable Machine Learning Analysis of the Chilean National Health Survey.Diagnostics (Basel, Switzerland) · 2026Article
- Sustainable Use of Natural Resources and Traditional Medicine in Tropical Countries: Uncovering the Main Antioxidant Compounds and Antihypertensive Potential of thePlants (Basel, Switzerland) · 2026Article
- The Evolution of Blood Pressure Thresholds and Targets over Time: A Historical Review.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arterial hypertension (HTN) represents the major cardiovascular risk factor and still represents a global health issue. In the last two years, three international societies published the new guidelines for the treatment of HTN (European Society of Cardiology, 2025; European Society of Hypertension, 2023; and American College of Cardiology in collaboration with American Heart Association, 2025), with many novelties which have been the object of many discussions among experts. The increased stress on screening programs, the new lower targets to reach by medical treatment, and the new strategies for resistant hypertension have raised some doubt on the feasibility of these recommendations in clinical practice. In this perspective document, the authors highlight and discuss the novelties and potential pros and cons of the new international recommendations for the treatment of arterial HTN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.